by Mybiogate | Dec 23, 2020 | Interview
Authors: Ziyi Xu, Chun Chen Editor: Ginger Ding In the 11 years from its debut in 2009 to its IPO on the Hong Kong Stock Exchange in 2020, Kintor Pharmaceutical has had 5 clinical-stage products under development and carried out multiple phase I-III clinical... 
by Mybiogate | Dec 18, 2020 | Industry Research
Author: Dr. Ginger Ding As a target of extensive research, NLRP3 is the culprit behind a long list of inflammation-related diseases including diabetes, gout, Alzheimer’s disease, NASH, inflammatory bowel disease, and atherosclerosis. However, NLRP3 does... 
by Mybiogate | Dec 17, 2020 | Chinese company profile
China Grand Pharmaceutical and Healthcare Holdings Limited 2019 Revenue: US$ 850.2 million Number of Employees: 8,000+ Founded: 1995 Overview China Grand Pharmaceutical and Healthcare Holdings Limited (512.HK) is a global pharmaceutical enterprise, principally engaged... 
by Mybiogate | Dec 10, 2020 | Industry Research
Author: HE Sheng As the world’s major companies release their 2020 Q3 reports, the latest global drug ranking top 20 list has also been announced. The total sales of the Top 20 drugs were US$114.4 billion. At the top of the list, Humira is still the king.... 
by Mybiogate | Dec 8, 2020 | China Market
Author: HE Sheng Recently, the Hurun Research Institute released their list of “Hurun’s 2020 Top Chinese 500 Private Enterprises”, ranked according to the companies’ market value or valuation. The market value of listed companies is calculated based on...